Mashup Score:5
UroToday# GU21
Mashup Score:2
UroTodayASCO GU 2021 Genitourinary Cancers Symposium Cabazitaxel second-line chemotherapy setting, feasibility and efficacy of cabazitaxel in patients with...
-
Cabazitaxel multiple rechallenges in metastatic castration-resistant #ProstateCancer: a therapeutic option to increase overall survival? Presentation by @CedricPobel @HopitalPompidou. #GU21 written coverage by @WallisCJD @VUMCurology on UroToday > https://t.co/Y8El70bXmp @ASCO https://t.co/Y8El70bXmp - view on twitter
Mashup Score:1
UroTodayASCO GU 2021 Genitourinary Cancers Symposium Cabazitaxel second-line chemotherapy setting, feasibility and efficacy of cabazitaxel in patients with...
-
Cabazitaxel multiple rechallenges in metastatic castration-resistant #ProstateCancer: a therapeutic option to increase overall survival? Presentation by @CedricPobel @HopitalPompidou. #GU21 written coverage by @WallisCJD @VUMCurology on UroToday > https://t.co/Y8El70tyKZ @ASCO https://t.co/Y8El70tyKZ - view on twitter
2021 ASCO GU Cancers Symposium CARD trial, cabazitaxel treatment demonstrated significantly improved progression-free survival (rPFS) and overall survival (OS), assessing the role of circulating...
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant #ProstateCancer from the #CARD trial. Presentation by @jodebon @ICR_London. #GU21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/NwB4eZXwY6 @ASCO #ASCOGU https://t.co/NwB4eZXwY6 - view on twitter